HOME >> MEDICINE >> NEWS
Defibrillators may improve survival in non-ischemic cardiomyopathy

Research from Northwestern University suggests that implantable cardioverter defibrillators (ICDs) can improve the survival rate of people who have a weakened heart muscle caused by factors unrelated to coronary artery disease a condition known as non-ischemic cardiomyopathy. Previous studies showed that people whose heart muscle had been weakened as a result of coronary artery disease (ischemic cardiomyopathy) could benefit from ICDs. This research is among the first to indicate that the approximately 200,000 other Americans who suffer from this condition may also benefit.

An ICD is a small device implanted under the skin near the collarbone and connected to the heart with insulated wires called leads. ICDs deliver shocks and other electrical therapies to the ventricles to stop ventricular tachyarrhythmias (abnormally fast heart rhythms originating in the heart's lower chambers).

Initial results from the DEFINITE (Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation) ICD were presented today at the American Heart Association's Scientific Sessions 2003 conference in Orlando, Florida by principal investigator Alan Kadish, M.D., Chester D. and Deborah M. Cooley Professor of Medicine from Feinberg School of Medicine at Northwestern University in Chicago.

The DEFINITE study, initiated in May 1998, followed 458 participants at 48 medical centers in the United States and Israel. Participants were randomized into two groups -- one receiving standard heart failure drug therapy (control group) and the other receiving drug therapy plus an implant of a St. Jude Medical ICD. The goal was to evaluate whether the ICDs offered an overall survival benefit to those who received them.

During the study, overall mortality at two years was 13.8 percent in the standard therapy (control) group versus 8.1 percentin the ICD group. Though these results did not reach the level of statistical significance defined in the study protocol, they do show
'"/>

Contact: Elizabeth Crown
e-crown@northwestern.edu
312-503-8928
Northwestern University
11-Nov-2003


Page: 1 2

Related medicine news :

1. Hormonal treatment improves survival in high-risk prostate cancer patients
2. New technique shows promise for improved straightening of crooked nose
3. Balance and better interactions between primary-care and specialist physicians improve US health
4. Cornea transplants can be improved
5. Growth hormone treatment improves symptoms of metabolic disorder in postmenopausal women
6. New treatment options for some difficult cancers improve survival and quality of life
7. New substance that improves the photodetection of bladder cancer gains market approval
8. Most advanced CT scanner improves imaging of heart, avoids need for surgical inspection
9. Increasing physician volume requirement could improve mammogram accuracy, study concludes
10. Columbia study finds hemophilia therapy dramatically improves outcomes for bleeding stroke
11. OHSU scientists develop MRI approach to improve breast cancer detection

Post Your Comments:
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma Applied ... Mesothelioma Patient Registry Act of 2015’. The bill was introduced in Congress yesterday ... (R-NY), Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose ...
(Date:7/30/2015)... ... July 30, 2015 , ... Boston Web Marketing ... All-Stars Summit. Google Partners is the platform for search marketing agencies to communicate ... and tools necessary to run successful search marketing campaigns. Google Partners also affords ...
(Date:7/30/2015)... ... July 30, 2015 , ... Ocean Hills Recovery has officially been accredited by ... recommendations.” No recommendations means CARF found no areas in the OHR program that needed ... 3% of all facilities receive. In addition, Ocean Hills was granted the maximum certification ...
(Date:7/30/2015)... New York, NY (PRWEB) , ... July 30, ... ... of Medicine at Mount Sinai Earns National Cancer Institute Designation , The Tisch ... been named a National Cancer Institute (NCI)-designated cancer center. TCI joins an elite ...
(Date:7/30/2015)... ... July 30, 2015 , ... 1Heart Caregiver Services LLC is offering its ... Make Money in the Booming Homecare Business.” This will be held in its main ... , The event will be hosted by 1Heart’s very own Randy Clarito (Director of ...
Breaking Medicine News(10 mins):Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2
(Date:7/30/2015)... 30, 2015  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, today ... year 2015 financial results after the market close on ... follow on the same day at 4:30 p.m. ET. ... Chief Executive Officer, and Rick Eiswirth , Chief ...
(Date:7/30/2015)... , Net Sales of $1.17 billion represent a decrease of ... of 5.7% constant currency , Reported net loss per ... per share were $1.59, an increase of 0.6% over the ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ...  The Company reported second quarter net sales of $1.17 billion, ...
(Date:7/29/2015)... Ill. , July 30, 2015  Astellas ... ACTIVE study evaluating the efficacy and safety of ... CRESEMBA® (isavuconazonium sulfate), under development for adults with ... Results from the study demonstrated that the trial ... in overall treatment response in isavuconazole-treated patients at ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 2Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 3Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 4Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 5Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 6Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 7Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 8Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 9Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 10Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 11Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 12Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 13Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 14Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 15Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 16Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 17Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 18Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 19Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 20Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 21Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 22Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 23Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 24Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 25Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 26Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 27Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 28Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 29Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5
Cached News: